Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 20, 2010, Pages 6020-6023

  Tang, Guozhi ^a   Kertesz, Denis J ^b   Yang, Minmin ^a,c   Lin, Xianfeng ^a   Wang, Zhanguo ^a   Li, Wentao ^a   Qiu, Zongxing ^a   Chen, Junli ^a   Mei, Jianghua ^a   Chen, Li ^a   Mirzadegan, Taraneh ^b,d   Harris, Seth F ^b,e   Villaseñor, Armando G ^b   Fretland, Jennifer ^b   Fitch, William L ^b   Hang, Julie Qi ^b   Heilek, Gabrielle ^b   Klumpp, Klaus ^b  

^a Roche RandD Center China Ltd   (China)

^b ROCHE BIOSCIENCE   (United States)

^c Pharmablock R and D Co Ltd   (China)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e GENENTECH INC   (United States)

Author keywords

HIV 1; Non nucleoside reverse transcriptase; Non nucleoside reverse transcriptase inhibitor (NNRTI)

Indexed keywords

BENZENE DERIVATIVE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PIPERIDINE 4 YL AMINOPYRIMIDINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CLEARANCE; CRYSTALLOGRAPHY; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION; PIPERIDINES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77956908369     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.08.068     Document Type: Article

References (17)

1. E. De Clercq Chem. Biodivers. 1 2004 44
2. J. Balzarini Curr. Top. Med. Chem. 4 2004 921
3. M.A. Wainberg J. Acquir. Immune Defic. Syndr. 34 2003 S2
4. C. Delaugerre, R. Rohban, A. Simon, M. Mouroux, C. Tricot, R. Agher, J.M. Huraux, C. Katlama, and V. Calvez J. Med. Virol. 65 2001 445
5. Z.K. Sweeney, and K. Klumpp Curr. Opin. Drug Discov. Devel. 11 2008 458
6. J.V. Madruga, P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, A. Mills, G. Pialoux, T. Wilkin, M. Peeters, J. Vingerhoets, and G. de Smedt Lancet 370 2007 29
7. J. Ren, P.P. Chamberlain, A. Stamp, S.A. Short, K.L. Weaver, K.R. Romines, R. Hazen, A. Freeman, R.G. Ferris, C.W. Andrews, L. Boone, J.H. Chan, and D.K. Stammers J. Med. Chem. 51 2008 5000
8. S.L. Davies, J. Castaner, J.S. Silvestre, and M. Bayes Drugs Future 30 2005 462
9. C. Sahlberg, and X. Zhou Anti-infect. Agents Med. Chem. 7 2008 101
10. D.J. Kertesz, C. Brotherton-Pleiss, M. Yang, Z. Wang, X. Lin, Z. Qui, D.R. Hirschfeld, S. Gleason, T. Mirzadegan, P.W. Dunten, S.F. Harris, A. Villaseñor, J.Q. Hang, G.M. Heilek, and K. Klumpp Bioorg. Med. Chem. Lett. 20 2010 4025
11. For a more detailed description of these syntheses see: Kertesz, D. J.; Brotherton-Pleiss, C.; Yang, M. US 2008/0146595.
12. 50 values were obtained from a SPA heteropolymeric assay. RNA-dependent DNA polymerase activity was measured using a biotinylated primer oligonucleotide and tritiated dNTP substrate. Newly synthesized DNA was quantified by capturing the biotinylated primer molecules on streptavidin coated Scintillation Proximity Assay (SPA) beads (Amersham). Each value represents the average of at least two independent assays.
13. D.W. Ludovici, B.L. De Corte, M.J. Kukla, H. Ye, Y.H. Chih, M.A. Lichtenstein, R.W. Kavash, A. Koen, M.P. de Bethune, H. Azijn, R. Oauwels, P.J. Lewi, J. Heeres, L.M.H. Koymans, M.R. de Jonge, K.J.A. Van Aken, F.F.D. Daeyaert, K. Das, E. Arnold, and P.A.J. Janssen Bioorg. Med. Chem. Lett. 11 2001 2235
14. 50 values were obtained following incubation of compound with infected MT4 cells in the presence of 10% fetal bovine serum. The assay assesses the reduction in the cytopathic effect of HIV-1 on MT4 cells in the presence of HIV-RT inhibitors. Each value represents the average of at least two independent assays. For a detailed description of the antiviral assay see: Pauwels, R.; De, C. E.; Desmyter, J.; Balzarini, J.; Goubau, P.; Herdewijn, P.; Vanderhaeghe, H.; Vandeputte, M. J. Virol. Methods, 1987, 16, 171.
15. Determination of potency versus wild type virus was repeated in the presence of 40% human serum (HS) for these compounds. The resulting 'protein shifted potency' as compared to the result with 10% FBS (see Ref. 14) is considered an indicator of potential for in vivo activity.
16. J. Wang, W. DeMaio, A. Chandrasekaran, L. Shen, A. Bach II, J. Scatina, and R. Talaat Curr. Drug Discovery Technol. 3 2006 101
17. Atomic coordinates for the structure of 11 bound to HIV-RT were deposited with the RCSB Protein Data Bank (PDB) under the access code 3 NBP.